VILDAGLIPTIN 50mg. IP + METFORMIN 500mg. IP

An anti-diabetic drug that reduces glycemia in patients with type 2 diabetes mellitus. (B Ahrén, 2011) Enhances pancreatic islet cell responsiveness to glucose. (Degrande, 2008) Improves the impaired sensitivity of the beta cells to glucose. (Foley, 2019) A well-tolerated and efficacious medicine in improving glycemic control in patients with type 2 diabetes mellitus. (Degrande, 2008) Provides superior efficacy and allows more patients to reach their glycemic targets. (Serge Halimi, 2008) Shows statistically significant and clinically meaningful reductions in HbA1c in patients with type 2 diabetes. (Serge Halimi, 2008) An effective therapy for glycemic control with a low risk of hypoglycemia. (L Cai, 2012) A safe option for managing patients with type 2 diabetes mellitus. (Chantal Mathieu, 2017) An efficacious candidate in reducing glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose levels. (Prato, 2007) Provides superior efficacy to monotherapy treatments with a comparable overall tolerability profile and low risk of hypoglycemia in type 2 diabetes patients. (E Bosi, 2009)